Medscape

Immune Status Does Not Affect Thyroid Cancer Prognosis

Differentiated thyroid cancer shows a comparable prognosis in patients with immunocompromised vs immunocompetent status, a ...
CURE

Understanding Stage 3 Papillary Thyroid Cancer: A Patient-Oncologist Discussion Guide

This guide provides an informative and educational overview of stage 3 papillary thyroid cancer (PTC) to help drive a ...
Medindia on MSN

Study Warns of Rising Thyroid Cancer Rates Worldwide

Chennai, Nov. 28 -- Highlights: ...

FDA approves label update for UNLOXCYT™ (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamo…

As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition ...
Le Lézard

FDA approves label update for UNLOXCYTtm (cosibelimab-ipdl) based on longer-term data that demonstrated improved clinical outcomes in advanced cutaneous squamous cell carcinoma ...

As the first and only PD-L1 immune checkpoint inhibitor approved for aCSCC, UNLOXCYT is an evolution in checkpoint inhibition, offering a balance of durable clinical responses and acceptable ...